Magazine Article | October 3, 2022

Data: The Future Of Regulatory Info Management In Europe

Source: Life Science Leader

By Frits Stulp and Aida Demneri

During the pandemic, it became clear that the time to get a product approved and to market is too long and protracted in the EU. Although extraordinary measures were taken during the past two years so that vaccines and critical medicines could be brought safely to market at greater speed, this was achieved largely by extending the working hours of assessors. Now that market expectations have been raised, there is a new sense of urgency for the EC (European Community) and EMA around transforming approval processes more permanently and sustainably.

access the Magazine Article!

Get unlimited access to:

Trend and Thought Leadership Articles
Case Studies & White Papers
Extensive Product Database
Members-Only Premium Content
Welcome Back! Please Log In to Continue. X

Enter your credentials below to log in. Not yet a member of Life Science Leader? Subscribe today.

Subscribe to Life Science Leader X

Please enter your email address and create a password to access the full content, Or log in to your account to continue.


Subscribe to Life Science Leader